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Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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Abstract
Background: To facilitate the clinical implementation of genomic medicine by next-generation sequencing, it will
be critically important to obtain accurate and consistent variant calls on personal genomes. Multiple software tools
for variant calling are available, but it is unclear how comparable these tools are or what their relative merits in
real-world scenarios might be.
Methods: We sequenced 15 exomes from four families using commercial kits (Illumina HiSeq 2000 platform and
Agilent SureSelect version 2 capture kit), with approximately 120X mean coverage. We analyzed the raw data using
near-default parameters with five different alignment and variant-calling pipelines (SOAP, BWA-GATK, BWA-SNVer,
GNUMAP, and BWA-SAMtools). We additionally sequenced a single whole genome using the sequencing and
analysis pipeline from Complete Genomics (CG), with 95% of the exome region being covered by 20 or more
reads per base. Finally, we validated 919 single-nucleotide variations (SNVs) and 841 insertions and deletions
(indels), including similar fractions of GATK-only, SOAP-only, and shared calls, on the MiSeq platform by amplicon
sequencing with approximately 5000X mean coverage.
Results: SNV concordance between five Illumina pipelines across all 15 exomes was 57.4%, while 0.5 to 5.1% of
variants were called as unique to each pipeline. Indel concordance was only 26.8% between three indel-calling
pipelines, even after left-normalizing and intervalizing genomic coordinates by 20 base pairs. There were 11% of
CG variants falling within targeted regions in exome sequencing that were not called by any of the Illumina-based
exome analysis pipelines. Based on targeted amplicon sequencing on the MiSeq platform, 97.1%, 60.2%, and 99.1%
of the GATK-only, SOAP-only and shared SNVs could be validated, but only 54.0%, 44.6%, and 78.1% of the GATK-
only, SOAP-only and shared indels could be validated. Additionally, our analysis of two families (one with four
individuals and the other with seven), demonstrated additional accuracy gained in variant discovery by having
access to genetic data from a multi-generational family.
Conclusions: Our results suggest that more caution should be exercised in genomic medicine settings when
analyzing individual genomes, including interpreting positive and negative findings with scrutiny, especially for
indels. We advocate for renewed collection and sequencing of multi-generational families to increase the overall
accuracy of whole genomes.
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Figure 2. Flow chart of our variant analysis pipeline. 
* Both Scalpel and CADD are still inpress. For CADD,  see http://cadd.gs.washington.edu/
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If	  we	  focus	  on	  variants	  called	  by	  at	  least	  two	  pipelines,	  i.e.	  the	  central	  region	  surrounded	  
by	  red	  dash	  lines,	  we	  can	  reduce	  algorithm-­‐induced	  error	  and	  achieve	  a	  signiﬁcant	  higher	  
power,	  82.6%	  for	  SNPs	  and	  72.9%	  for	  INDELs,	  respec[vely.	  
	  
VigneKe	  #1:	  Variable	  expressivity	  in	  any	  disease,	  
including	  in	  this	  one:	  	  Ogden	  Syndrome	  in	  	  
Ogden,	  Utah.	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Am	  J	  Hum	  Genet.	  2011	  Jul	  15;89(1):28-­‐43.	  	  
These	  are	  the	  Major	  Features	  of	  the	  Syndrome.	  
Categorical	  Thinking	  Misses	  Complexity	  
A	  conceptual	  model	  of	  genotype-­‐phenotype	  correlaTons.	  	  The	  y	  plane	  represents	  a	  
phenotypic	  spectrum,	  the	  x	  plane	  represents	  the	  canalized	  progression	  of	  development	  
through	  [me,	  and	  the	  z	  plane	  represents	  environmental	  ﬂuctua[ons.	  	  	  
Time	  
Environment	  
Phenotypic	  
Spectrum	  

Expression	  Issues	  
•  We	  do	  not	  really	  know	  the	  expression	  of	  
preMy	  much	  ALL	  muta[ons	  in	  humans,	  as	  we	  
have	  not	  systema[cally	  sequenced	  or	  
karyotyped	  any	  gene[c	  altera[on	  in	  
Thousands	  to	  Millions	  of	  randomly	  selected	  
people,	  nor	  categorized	  into	  ethnic	  classes,	  i.e.	  
clans.	  
•  Complexity,	  or	  “The	  False	  Nega[ve	  Problem”	  
	  
Genotype	  ≠	  Phenotype	  
Environment	  maMers!	  
Ancestry	  maMers!	  
Genomic	  background	  maMers!	  
Longitudinal	  course	  maMers!	  
	  
Summary	  from	  VigneKe	  #1	  
VigneKe	  #2:	  Another	  family	  in	  Utah:	  New	  Syndrome	  
with	  Intellectual	  Disability,	  “AuTsm”,	  “ADHD”	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
1.5	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  years	  old 	  	  
3	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  years	  old
	  	  
Dysmorphic	  
Mental	  Retarda[on	  
“au[sm”	  
“ADHD”	  
Hearing	  diﬃcul[es	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  gene[c	  tests	  nega[ve,	  including	  nega[ve	  
for	  Fragile	  X	  and	  MANY	  candidate	  genes.	  
•  Whole genome sequencing was performed using : 
–  Complete Genomics sequencing and analysis 
pipeline v2.0 
–  llumina HiSeq 2000 sequencing platform.  
•  Illumina reads were mapped to the hg19 reference genome 
using BWA v. 0.6.2-r126 
•  Variant detection was performed using the GATK v. 2.4-9.   
•  A second analytical pipeline was used to map reads to the 
hg19 reference genome using Novoalign, and variants were 
also detected using the FreeBayes caller. 
•  Standard approaches can then be used to 
identify potentially deleterious mutations 
conforming to classical disease models for 
genetic disorders.   
 
•  We subset the full dataset to evaluate 
differences between raw numbers of 
mutations detected between different data 
sets:  
–  WGS data from the nuclear family,  
–  WGS from a larger portion of the family.	  
Using only nuclear family: 
55195 Variants were found to be de-novo in the two affected boys  
122 were coding : 
107 non-synonymous missense 
4 splicing  
3 frame-shift deletions 
3 frame-shift insertions 
2 frame-shift substitutions 
2 stop-gain  
1 stop-loss 
26514 Variants were found to conform to an X-linked disease model 
28 were coding: 
27 non-synonymous missense 
1 splicing 
Using information from a greater portion of the family structure: 
17726 Variants were found to be de-novo in the two affected boys  
40 were coding : 
32 non-synonymous missense 
3 splicing  
2 frame-shift deletions 
1 stop-loss 
1 frame-shift insertion 
1 frame-shift substitution 
2824 Variants were found to conform to an X-linked disease model 
4 were coding: 
3 non-synonymous missense 
1 splicing 
•  The	  numbers	  of	  muta[ons	  diﬀer	  as	  expected	  
between	  these	  two	  sets	  of	  analyses:	  	  
	  
– More	  muta[ons	  are	  ﬁltered	  when	  a	  greater	  
por[on	  of	  the	  family	  is	  incorporated	  into	  the	  
analysis.	  	  	  
	  
– This	  is	  likely	  due	  to	  false	  posi[ve	  and	  false	  
nega[ve	  rates	  across	  sequencing	  and	  informa[cs	  
plamorms.	  
Using only nuclear family: 
De-novo ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 PRAMEF4 0.00192 0.00144,0.00265 13.13 chr1:12939476;13.13;G->C;N->K;0,1 
2 PRAMEF10 0.00318 0.00243,0.00417 20.77 chr1:12954852;20.77;T->C;H->R;3,2 
3 LOC440563 0.00523 0.00416,0.00653 9.89 chr1:13183056;9.89;T->C;N->D;0,1 
X-linked ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 ASB12 0.000898 0.000898,0.00119 18.7 chrX:63444792;18.70;C->A;G->C;0,1 
2 TAF1 0.00153 0.00117,0.00214 14.59 chrX:70621541;14.59;T->C;I->T;0,1 
3 ZNF41 0.002 0.0015,0.00275 12.9 chrX:47307978;12.90;G->T;D->E;0,1 
Using information from a greater  
portion of the family structure: 
De-novo ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 PRAMEF10 0.00342 0.00262,0.00445 20.77 chr1:12954852;20.77;T->C;H->R;3,2 
X-linked ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 TAF1 0.002 0.0015,0.00275 14.59 chrX:70621541;14.59;T->C;I->T;0,1 
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Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
Sarah A. Shoichet,1 Kirsten Hoffmann,1 Corinna Menzel,1 Udo Trautmann,2 Bettina Moser,1
Maria Hoeltzenbein,1 Bernard Echenne,3 Michael Partington,4 Hans van Bokhoven,5
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3Centre Hospitalier Universitaire de Montpellier, Hoˆpital Saint-Eloi, Montpellier, France, 4Hunter Genetics and University of Newcastle,
Waratah, Australia; 5Department of Human Genetics, University Medical Centre, Nijmegen, The Netherlands; 6Services
de Ge´ne´tique–INSERM U316, CHU Bretonneau, Tours, France; 7Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium;
and 8Institut Cochin de Ge´ne´tique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris
Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
Received July 22, 2003; accepted for publication September 25, 2003;
electronically published November 18, 2003.
Address for correspondence and reprints: Dr. Vera Kalscheuer,Max-
Planck-Institute for Molecular Genetics, Ihnestrasse 73, D-14195Berlin,
Germany. E-mail: kalscheu@molgen.mpg.de
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
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Figure 4 A, Pedigree of family P13, with sequence corresponding to the prolinerleucinemutation (left to right): unrelated control individual,
mother (II:1), index patient (III:2), and brother of the index patient (III:1). For the potentially affected female cousin (individual III-4) (indicated
with an asterisk [*]), no clinical data are available. Affected nucleotides are indicated with black arrows. B, Pedigree for family P42, with
sequence chromatograms indicating the splice-site mutation in affected individuals (left to right): father (I:1), mother (I:2), index patient (II:1),
and mildly affected sister (II:2). Uppercase letters indicate coding sequence; affected nucleotides are indicated with black arrows.
a diagnosis of mild MR. He was born at term (by Ce-
sarean section), with a birth weight of 3,000 g (10th–25th
percentile) and a length of 51 cm (50th percentile). He
walked at age 12–13 mo and reached early milestones
within the normal time frame; however, he exhibited a
severe language delay. He first made two-word associa-
tions at age 3 years and was first speaking in simple
phrases at age 4 years 6 mo. At age 8 years, he was 135
cm tall (90th percentile) and had a head circumference
of 53 cm (75th percentile). He had no additional dys-
morphic or neurological symptoms, and results of
screening for fragile X were negative. At age 10 years 3
The	  two	  brothers	  with	  the	  P111L	  
muta[ons	  reported	  in	  the	  prior	  
paper	  do	  have	  mental	  deﬁciency,	  
hyperkinesia,	  no	  motor	  or	  
neurologic	  sign	  except	  for	  the	  
delay,	  and	  slight	  dysmorphic	  facial	  
anomalies:	  large	  low-­‐set	  ears,	  thin	  
upper	  lip,	  slight	  downward	  
palpebral	  slants,	  but	  no	  upturned	  
nose,	  and	  a	  short	  philtrum.	  The	  
mother	  was	  normal	  in	  appearance.	  	  
•  KRAB	  (Kruppel-­‐associated	  box)	  domain	  -­‐A	  box.	  
•  The	  KRAB	  domain	  is	  a	  transcrip[on	  repression	  module,	  found	  
in	  a	  subgroup	  of	  the	  zinc	  ﬁnger	  proteins	  (ZFPs)	  of	  the	  C2H2	  
family,	  KRAB-­‐ZFPs.	  KRAB-­‐ZFPs	  comprise	  the	  largest	  group	  of	  
transcrip[onal	  regulators	  in	  mammals,	  and	  are	  only	  found	  in	  
tetrapods.	  	  
•  The	  KRAB	  domain	  is	  a	  protein-­‐protein	  interac[on	  module	  
which	  represses	  transcrip[on	  through	  recrui[ng	  corepressors.	  
The	  KAP1/	  KRAB-­‐AFP	  complex	  in	  turn	  recruits	  the	  
heterochroma[n	  protein	  1	  (HP1)	  family,	  and	  other	  chroma[n	  
modula[ng	  proteins,	  leading	  to	  transcrip[onal	  repression	  
through	  heterochroma[n	  forma[on.	  
ZNF41	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Figure 6 Northern blot hybridization of ZNF41, by use of a probe corresponding to nucleotides 621–1099 of ZNF41 transcript variant
1. A, Adult tissues (left to right): heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. B, Fetal tissues (left to right): brain,
lung, liver, and kidney.C,Adult brain structures (left to right): amygdala, caudate nucleus, corpus callosum, hippocampus, whole brain, substantia
nigra, and thalamus. Black arrowheads highlight the presence of a novel 6-kb transcript. Actin (A and C) or GAPDH (B) served as controls
for RNA loading.
sible for sequence-specific DNA binding. ZNF41, absent
in our patient, is a member of the subfamily of Krueppel-
type zinc-finger proteins harboring a highly conservedN-
terminal domain known as the Krueppel-associated box
(KRAB). Although the specific functions of ZNF41 are
not fully understood, various related genes play an es-
tablished and important role in human development and
disease (Ladomery and Dellaire 2002). In another female
patient with severe MRX and a balanced translocation,
the disorder probably resulted from the disruption of a
related X-chromosomal zinc-finger gene (Lossi et al.
2002). The X-chromosome breakpoint was located just
upstream of the Krueppel-like factor 8 (KLF8 [MIM
300286]), also known as the “ZNF741 gene,” and it was
confirmed that KLF8 transcripts were absent in the pa-
tient cell line. The Wilms tumor suppressor gene WT1
(MIM 194070), which harbors four Krueppel-type zinc
fingers, has been implicated in several urogenital devel-
opmental disorders, including WAGR syndrome (MIM
194072), which is associated with MR (Call et al. 1990;
Rose et al. 1990; Gessler et al. 1992). Of particular rel-
evance, however, are the biochemical studies that high-
light the links between the highly conserved KRAB/ZFP
subfamily of zinc-finger proteins and chromatin remod-
eling. Many disorders, several of which are associated
with MR, have been linked to defects in processes that
govern chromatin structural modification (Hendrich and
Bickmore 2001), suggesting that chromatin structural
regulationmay play a specific and important role in path-
ways critical for mental function.
Repression of transcription by a KRAB/ZFP requires
binding of the corepressor KAP-1 (also known as
“TIF1b” and “KRIP-1” [MIM 601742]) (Friedman et
al. 1996; Kim et al. 1996; Moosmann et al. 1996; Peng
et al. 2000a, 2000b). KAP-1 is a molecular scaffold that
coordinates gene-specific silencing by recruiting both
heterochromatin-associated proteins (Ryan et al. 1999)
and by interacting with the novel histone H3 Lys9–
specific methyltransferase SETDB1 (MIM 604396)
(Schultz et al. 2002). It is interesting that, within the
primary sequence of SETDB1, Schultz et al. (2002) iden-
tified a methyl CpG–binding domain that is related to
the domain found in the methyl CpG binding protein
MeCP2, which is mutated both in patients with Rett
syndrome (MIM 312750) (Amir et al. 1999) and in
patients with MRX (Couvert et al. 2001; Yntema et al.
2002). Like ZNF41, MECP2 is ubiquitously expressed;
yet loss of functional protein results in a neurological
phenotype. Although the mechanism by whichMECP2
mutations cause MR is not clear, it is well established
that MeCP2 binds to methylated CpGs and represses
transcription (for review, see Ballestar and Wolffe
[2001]), and it has recently been shown that MeCP2
associates with an unidentified methyltransferase that
specifically methylates Lys9 of histone H3 (Fuks et al.
2003), as does the KAP-1/KRAB/ZFP binding partner
SETDB1.
Further characterization of the KRAB/KAP-1 repres-
sor module has indicated that, in addition to the KRAB
domain, a bipartite domain of the plant homeodomain
(PHD) finger and a bromodomain, located within the C-
terminal portion of KAP-1, are also required for effective
gene silencing (Schultz et al. 2002). It is interesting that
the point mutations in that study were modeled after
naturally occurring mutations in the PHD finger of the
human ATRX gene, which has been implicated in both
X-linked a-thalassemia/MR syndrome (MIM 301040)
(Gibbons et al. 1995) and Juberg-Marsidi syndrome
(MIM 309590), which is also associated with MR (Vil-
lard et al. 1996a). In light of the fact that the PHD
Proving	  the	  relevance	  of	  this	  mutaTon	  
•  Will	  need	  to	  ﬁnd	  a	  second,	  unrelated	  family	  with	  same	  exact	  mu a[on	  and	  
similar	  phenotype.	  
•  Can	  also	  p rform	  in	  vitro/in	  vivo	  studies	  an 	  struct ral	  mod ling,	  and	  make	  
knock-­‐in	  mice	  and/or	  test	  in	  zebraﬁsh,	  etc…	  for	  biological	  func[on.	  

•  Previously	  reported	  P111L	  change	  in	  the	  
ZNF41	  protein	  has	  now	  also	  been	  found	  in	  two	  
"male	  controls"	  (EVS	  server,	  ESP6500),	  and	  
furthermore,	  there	  are	  two	  rare,	  likely	  
heterozygous	  ZNF41	  frameshit	  muta[ons	  and	  
one	  heterozygous	  stop-­‐gained	  muta[on	  
reported	  in	  control	  individuals	  (ESP6500)	  
(personal	  communica[on	  from	  Dr.	  Vera	  
Kalscheuer).	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XLID-Causing Mutations and Associated Genes Challenged
in Light of Data From Large-Scale Human Exome Sequencing
Ame´lie Piton,1,2,4,* Claire Redin,1,2,4 and Jean-Louis Mandel1,2,3,*
Because of the unbalanced sex ratio (1.3–1.4 to 1) observed in intellectual disability (ID) and the identification of large ID-affected fam-
ilies showing X-linked segregation, much attention has been focused on the genetics of X-linked ID (XLID). Mutations causing mono-
genic XLID have now been reported in over 100 genes, most of which are commonly included in XLID diagnostic gene panels. Nonethe-
less, the boundary between true mutations and rare non-disease-causing variants often remains elusive. The sequencing of a large
number of control X chromosomes, required for avoiding false-positive results, was not systematically possible in the past. Such infor-
mation is now available thanks to large-scale sequencing projects such as the National Heart, Lung, and Blood (NHLBI) Exome
Sequencing Project, which provides variation information on 10,563 X chromosomes from the general population. We used this NHLBI
cohort to systematically reassess the implication of 106 genes proposed to be involved in monogenic forms of XLID. We particularly
question the implication in XLID of ten of them (AGTR2, MAGT1, ZNF674, SRPX2, ATP6AP2, ARHGEF6, NXF5, ZCCHC12, ZNF41,
and ZNF81), in which truncating variants or previously published mutations are observed at a relatively high frequency within this
cohort. We also highlight 15 other genes (CCDC22, CLIC2, CNKSR2, FRMPD4, HCFC1, IGBP1, KIAA2022, KLF8, MAOA, NAA10,
NLGN3, RPL10, SHROOM4, ZDHHC15, and ZNF261) for which replication studies are warranted. We propose that similar reassessment
of reported mutations (and genes) with the use of data from large-scale human exome sequencing would be relevant for a wide range of
other genetic diseases.
Introduction
Intellectual disability (ID, formerly called mental retarda-
tion) is a developmental brain disorder commonly defined
by an IQ below 70 and limitations in both intellectual
functioning and adaptive behavior. ID can originate from
environmental causes and/or genetic anomalies, and its
incidence in children is estimated to be of 1%–2%.1,2 As
a result of an excess of males affected by ID (the male-to-
female ratio is 1.3–1.4 to 1) and the identification of
many families presenting with a clear X-linked segrega-
tion, much attention has been focused for the last 20 years
on genes located on the X chromosome and thus respon-
sible for X-linked ID (XLID, previously known as XLMR)
when mutated.3,4 One of the first genes identified as
involved in XLID is FMR1 (MIM 309550), a target of the
unstable expansion mutation responsible for fragile X syn-
drome (MIM 300624); accounting for about 1%–2% of all
ID cases, this mutation still remains the most common
cause of XLID.5,6 Since then, the number of genes involved
in XLID when mutated has grown exponentially,3,7,8 from
only 11 in 1992 to 43 in 2002 and over 100 genes now
identified thank to the efforts of various teams.4,9,10 Half
of the known genes carrying mutations responsible for
XLID appear to be associated with nonsyndromic or pauci-
syndromic forms; the other half are associated with more
syndromic forms (i.e., ID associated with defined clinical
or metabolic manifestations), which facilitates the identifi-
cation of causative mutations in the same gene because
unrelated probands with comparable phenotypes can
bemore easily matched. However, the presence of ‘‘milder’’
mutations (in RPS6KA3 [RSK2, MIM 300075] or ARX [MIM
300382], for instance) and/or incomplete penetrance of
specific clinical signs in some individuals carrying muta-
tions in genes associated with syndromic ID can blur the
distinction between syndromic and nonsyndromic ID.11
Various approaches have been developed for the identi-
fication of genes and associated causative mutations
responsible for XLID (see Lubs et al.4 for a review): (1) po-
sitional cloning based on chromosomal rearrangements or
copy-number variants (CNVs) affecting the X chromo-
some, (2) screening of genes located in candidate intervals
identified via linkage analysis in large XLID-affected fam-
ilies, (3) direct sequencing of candidate genes with a func-
tion or expression pattern that suggests a role in cognition
or that fits with metabolic or clinical observations in
affected subjects, and (4) high-throughput sequencing al-
lowing screening of mutations in all protein-coding re-
gions of the genome or only in the X chromosome (exome
versus X exome).10,12–14
The validation of potentially damaging mutations in a
gene newly associated with XLID requires functional
and/or genetic analyses, especially when the identification
is based on reportingmutations in very few families or sim-
plex cases. Functional studies are uneven in pertinence
and strength. They can include direct assessment of the
mutational impact at any of the protein, cellular, or
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Using information from a greater  
portion of the family structure: 
De-novo ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 PRAMEF10 0.00342 0.00262,0.00445 20.77 chr1:12954852;20.77;T->C;H->R;3,2 
X-linked ranked genes: 	  	   	  	   	  	   	  	   	  	  
RANK Gene p-value p-value-ci Score Variants 
1 TAF1 0.002 0.0015,0.00275 14.59 chrX:70621541;14.59;T->C;I->T;0,1 
Need	  to	  reduce	  the	  “False	  Nega[ve	  Problem”	  
	  
Genotype	  ≠	  Phenotype	  
Environment	  maMers!	  
Ancestry	  maMers!	  
Genomic	  background	  maMers!	  
Longitudinal	  course	  maMers!	  
	  
We	  can	  only	  begin	  to	  really	  understand	  this	  if	  we	  u[lize	  the	  
power	  of	  intense	  networking	  via	  internet-­‐enabled	  archiving	  
and	  distribu[on	  of	  data.	  
Summary	  from	  VigneKe	  #2	  
Down	  Syndrome	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